<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976206</url>
  </required_header>
  <id_info>
    <org_study_id>VSEL-face</org_study_id>
    <nct_id>NCT03976206</nct_id>
  </id_info>
  <brief_title>Very Small Embryonic-like Stem Cells for Facial Skin Antiaging</brief_title>
  <official_title>Autologous Very Small Embryonic-like Stem Cells(VSELs) for Facial Skin Antiaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Four-Leaf Clover HealthTech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the safety and efficacy of autologous very small embryonic-like stem
      cells(VSELs) to facial skin antiaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VSELs come from the patient's peripheral blood, and will be injected in left preauricular
      area, followed by skin pathology to compare the improvement of skin aging. Two 0.5 × 1 cm
      fragments of skin and subcutaneous tissue was removed from bilateral preauricular areas for
      morphologic analysis by optical and electron microscopy. Histologic analysis of skin biopsy
      specimens was performed by hematoxylin and eosin, picrosirius red (for visualization of
      collagen), and orcein (for visualization of elastic fibers) staining.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In the experimental group, VSELs will be injected in left preauricular area of every volunteer, followed by skin pathology to compare the improvement of skin aging with the skin of right preauricular area. In the control group, platelet-rich plasma will be injected to the left preauricular area of every volunteer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The volunteers will be randomly arranged to enter the experimental group or the control group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>1 week</time_frame>
    <description>Swelling in the skin at the injection site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>1 week</time_frame>
    <description>Color change, pain in the skin at the injection site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>1 week</time_frame>
    <description>Pain in the skin at the injection site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term changes in skin histopathology</measure>
    <time_frame>3-6 months after injection</time_frame>
    <description>Two 0.5 × 1 cm fragments of skin and subcutaneous tissue was removed from the bilateral preauricular areas for morphologic analysis by optical and electron microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term changes in skin histopathology</measure>
    <time_frame>12 months after final injection</time_frame>
    <description>Two 0.5 × 1 cm fragments of skin and subcutaneous tissue was removed from the bilateral preauricular areas for morphologic analysis by optical and electron microscopy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Skin Inflammation</condition>
  <arm_group>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Mini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Very small embryonic-like stem cell</intervention_name>
    <description>We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus</description>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_label>VSEL Mini</arm_group_label>
    <other_name>VSEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Healthy volunteers with anti-aging willingness

        Exclusion Criteria:

          -  Metabolic and systemic diseases such as diabetes and atherosclerosis

          -  Facial skin diseases such as herpes, eczema, skin rash, systemic lupus erythematosus,
             dermatomyositis, connective tissue disease

          -  Endocrine disorders and cancer patients Blood disease patients, thrombocytopenia or
             dysfunction, hypofibrinemia or anticoagulant therapy, long-term use of aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jibing Chen</last_name>
    <phone>+86-18903068207</phone>
    <email>jibingchen398@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biological treatment center in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Jibing, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

